Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for aggressive lymphoma: targeted drug combo enters trial

NCT ID NCT06005870

Recruiting now Disease control Sponsor: Huazhong University of Science and Technology Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests whether adding zanubrutinib to standard chemotherapy (R-CHOP) can better treat newly diagnosed diffuse large B-cell lymphoma that shows p53 protein expression. About 41 adults aged 18–75 will receive the combination. The main goal is to see how many patients achieve complete remission, with secondary aims of overall survival and safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
zanubrutinib combined with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)
What this could lead to
If successful, this combination could improve complete response rates and long-term outcomes for a hard-to-treat subtype of lymphoma with p53 expression.
What could go wrong
This is a small Phase 2 trial with only 41 participants, so results may not apply broadly. Adding zanubrutinib to R-CHOP may increase side effects like infections or bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE LARGE B CELL LYMPHOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    RECRUITING

    Wuhan, Hubei, 430022, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.